Compare AVA & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVA | BLLN |
|---|---|---|
| Founded | 1889 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Power Generation | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 1994 | N/A |
| Metric | AVA | BLLN |
|---|---|---|
| Price | $40.82 | $74.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $39.00 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 395.9K | 380.5K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | ★ 3.93 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $1,964,000,000.00 | N/A |
| Revenue This Year | $3.11 | $46.29 |
| Revenue Next Year | $4.44 | $30.14 |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $35.50 | $61.96 |
| 52 Week High | $43.50 | $138.70 |
| Indicator | AVA | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 42.81 |
| Support Level | $37.86 | $64.99 |
| Resistance Level | $42.02 | $83.20 |
| Average True Range (ATR) | 0.75 | 6.29 |
| MACD | -0.09 | -1.26 |
| Stochastic Oscillator | 34.30 | 15.26 |
Avista Corp is an electric and natural gas utility company. The company has two business segments including Avista Utilities, which provides electric distribution and transmission, and natural gas distribution services in parts of eastern Washington and northern Idaho, and also provides natural gas distribution service in parts of northeastern and southwestern Oregon. Avista Utilities has electric generating facilities in Washington, Idaho, Oregon, and Montana. AEL&P segment is a regulated utility providing electric services in Juneau, Alaska that is a wholly-owned subsidiary and the primary operating subsidiary of AERC.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.